Quarterly report pursuant to Section 13 or 15(d)

Going Concern (Details Narrative)

v3.20.4
Going Concern (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2020
May 01, 2020
Jan. 31, 2020
Sep. 30, 2019
Nov. 30, 2018
May 31, 2020
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Nov. 30, 2019
Cash and cash equivalents             $ 15,106       $ 15,106   $ 2,321  
Accounts receivable, net             7,239       7,239   10,338  
Total current assets             26,096       26,096   16,510  
Total current liabilities             16,098       16,098   17,292  
Net loss             5,580 $ 6,494 $ 5,304 $ 3,419 15,107 $ 8,630    
Net cash used in operating activities                     6,673 7,785    
Line of credit facility             3,400       3,400   $ 3,000  
Line of credit facility, remaining borrowing capacity                        
Cost of revenue             3,850   $ 3,031   9,963 $ 5,654    
Series B Preferred Stock [Member]                            
Public offering generating net proceeds     $ 19,500                      
Sale of common stock     20,000                      
Equity Distribution Agreement [Member]                            
Public offering generating net proceeds       $ 3,700                    
ATM Agreement [Member]                            
Public offering generating net proceeds                     $ 700      
Sale of common stock                     178,000      
Centers for Medicare & Medicaid Services [Member]                            
Loans payable   $ 2,100                        
Department of Health and Human Services [Member]                            
Loans payable   650                        
Other income   450                        
Cost of revenue   $ 200                        
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]                            
Proceeds from loans payable           $ 888                
Silicon Valley Bank [Member]                            
Line of credit facility term loan         3 years                  
Line of credit facility, description         The borrowing limit of the Revolving Line of Credit is the lower of 80% of the Company's eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months.           The amount that may be borrowed under the Revolving Line of Credit is the lower of: (i) $3.75 million or (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB). Revolving Line of Credit outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line of Credit facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line of Credit. The Revolving Line of Credit has a maturity date three years from the effective date, or November 13, 2021.      
Line of credit, percentage         0.50%                  
Line of credit facility, remaining borrowing capacity                        
Silicon Valley Bank [Member] | Maximum [Member]                            
Line of credit facility                           $ 4,000
Subsequent Event [Member]                            
Cash $ 5,200                          
Line of credit facility 3,400                          
Restricted cash 350                          
Subsequent Event [Member] | Silicon Valley Bank [Member]                            
Repayment of line of credit $ 3,400